MONTREAL and PARSIPPANY, N.J.--(BUSINESS WIRE)--July 18, 2006--TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in developing treatments for respiratory diseases, today announced preliminary data from its first Phase II clinical trial of inhaled TPI-ASM8 as a single agent in patients with allergic asthma. The results indicate that inhaled TPI-ASM8 demonstrated protection in early and late stage allergic responses in patients with asthma.
